- Ovid Therapeutics Inc To Host Research & Development (R&D) Day TranscriptOct 02, 2023
- Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 17, 2023
- Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 14, 2022
- Ovid Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Ovid Therapeutics Inc Annual Shareholders Meeting TranscriptJun 10, 2021
- Ovid Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 19, 2021
- Ovid Therapeutics Inc and Takeda Pharmaceutical Co Ltd to Discuss Strategic Transaction Call TranscriptMar 03, 2021
- Ovid Therapeutics Inc. - Special Call TranscriptOct 22, 2020
- Ovid Therapeutics Inc. - Special Call TranscriptAug 25, 2020
- Ovid Therapeutics Inc. - Special Call TranscriptJul 13, 2020
- Ovid Therapeutics Inc. - Special Call TranscriptJun 17, 2020
- Ovid Therapeutics Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- Ovid Therapeutics to Discuss Positive Initial Data from Ongoing ENDYMION Trial Call TranscriptSep 23, 2019
- Ovid Therapeutics Inc. - Special Call TranscriptJun 27, 2019
Ovid Therapeutics Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Angelman Syndrome and OV101 Seminar. (Operator Instructions) As a reminder, this call is being recorded.
I will now turn the call over to your host with Dawn Schottlandt. You may begin.
Thank you, operator. Good afternoon, everyone, and thank you for joining today's OV101 seminar.
Please note, we will have slides to accompany this call, which are also available through the webcast player on our website. We will also post the PDF of the webcast on our website following this conference call. As a reminder during today's call, we'll be making forward-looking statements.
Various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation may include, but are not limited to, statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)